# US 2018/0021355 A1 · Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021355 A1
- Document ID: US20180021355A1
- Status: Published application
- Kind: A1
- Application number: 15/720,830
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2007-04-25
- Assignees: Opko Renal, LLC
- Applicants: Opko Renal, LLC
- Inventors: Charles W. Bishop; Eric J. Messner
- Web page: https://patentgrep.com/patent/US20180021355A1

## CPC

- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 31/59: Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 5/18: of the parathyroid hormones
- A61P 5/20: for decreasing, blocking or antagonising the activity of PTH
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering 25-hydroxyvitamin D3 with or without 25-hydroxyvitamin D2 and, as necessary, 1,25-dihydroxyvitamin D2 as a Vitamin D hormone replacement therapy.

## Claims

### Claim 1

A method of treating and/or preventing secondary hyperparathyroidism in a patient suffering from chronic kidney disease, comprising increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the patient by administering sustained release 25-hydroxyvitamin D3 and optionally 25-hydroxyvitamin D2, wherein 25-hydroxyvitamin D3 is the predominant prohormone in circulation, in a patient receiving one or more medications that increase the catabolism of vitamin D, or phenytoin, or fosphenytoin, or phenobarbital, or carbamazepine, or rifampin, or one or more medications that reduce absorption of vitamin D, or cholestyramine, or colestipol, or orlistat, or a fat substitute, or one or more medications that inhibit activation of vitamin D, or ketoconazole, or one or more medications that decrease calcium absorption, or a corticosteroid, or any combination of the foregoing.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is receiving one or more medications that increase the catabolism of vitamin D, or phenytoin, or fosphenytoin, or phenobarbital, or carbamazepine, or rifampin.

### Claim 3 (depends on 2)

The method of claim 2, wherein the patient is receiving phenytoin.

### Claim 4 (depends on 2)

The method of claim 2, wherein the patient is receiving fosphenytoin.

### Claim 5 (depends on 2)

The method of claim 2, wherein the patient is receiving phenobarbital.

### Claim 6 (depends on 2)

The method of claim 2, wherein the patient is receiving carbamazepine.

### Claim 7 (depends on 2)

The method of claim 2, wherein the patient is receiving rifampin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the patient is receiving one or more medications that reduce absorption of vitamin D, or cholestyramine, or colestipol, or orlistat, or a fat substitute.

### Claim 9 (depends on 8)

The method of claim 8, wherein the patient is receiving cholestyramine

### Claim 10 (depends on 8)

The method of claim 8, wherein the patient is receiving colestipol

### Claim 11 (depends on 8)

The method of claim 8, wherein the patient is receiving orlistat

### Claim 12 (depends on 8)

The method of claim 8, wherein the patient is receiving a fat substitute.

### Claim 13 (depends on 1)

The method of claim 1, wherein the patient is receiving one or more medications that inhibit activation of vitamin D, or ketoconazole

### Claim 14 (depends on 13)

The method of claim 13, wherein the patient is receiving ketoconazole

### Claim 15 (depends on 1)

The method of claim 1, wherein the patient is receiving one or more medications that decrease calcium absorption, or a corticosteroid.

### Claim 16 (depends on 15)

The method of claim 15, wherein the patient is receiving a corticosteroid.
